Michael D Hogarty

List of Publications by Year
in descending order

88	8,293	87888 38	56724 83
papers	citations	h-index	g-index

94	94	94	9606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	21
2	Reduced ERâ€“mitochondria connectivity promotes neuroblastoma multidrug resistance. EMBO Journal, 2022, 41, e108272.	7.8	16
3	Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Childrenâ€™s Oncology Group (COG) risk stratification.. Journal of Clinical Oncology, 2022, 40, 10013-10013.	1.6	0
4	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with highâ€risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2021, 68, e28794.	1.5	29
5	Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nature Communications, 2021, 12, 511.	12.8	85
6	BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Pediatric Blood and Cancer, 2021, 68, e28933.	1.5	9
7	Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy, 2021, 27, 490.e1-490.e8.	1.2	14
8	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
9	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	1.6	174
10	MYCN-induced nucleolar stress drives an early senescence-like transcriptional program in hTERT-immortalized RPE cells. Scientific Reports, 2021, 11, 14454.	3.3	6
11	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	3.7	10
12	Pan-neuroblastoma analysis reveals age- and signature-associated driver alterations. Nature Communications, 2020, 11, 5183.	12.8	87
13	Fixing the leaky pipeline: identifying solutions for improving pediatrician-scientist training during pediatric residency. Pediatric Research, 2020, 88, 163-167.	2.3	10
14	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	1.6	0
15	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
16	Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells. Frontiers in Immunology, 2020, 11, 873.	4.8	20
17	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
18	MYCN amplification and ATRX mutations are incompatible in neuroblastoma. Nature Communications, 2020, 11, 913.	12.8	66

#	Article	IF	Citations
19	The ASPHO 2020 distinguished career award goes to Dr Garrett M. Brodeur. Pediatric Blood and Cancer, 2020, 67, e28191.	1.5	0
20	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Journal of Clinical Oncology, 2020, 38, 1906-1918.	1.6	41
21	Segmental chromosome aberrations and clinical response impact outcome of inss stage III patients â‰¥18 months with unfavorable histology and without MYCN amplification: A Childrenâ€™s Oncology Group (COG) report.. Journal of Clinical Oncology, 2020, 38, 10502-10502.	1.6	0
22	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Childrenâ€™s Oncology Group Study ANBL0531. Journal of Clinical Oncology, 2019, 37, 3243-3255.	1.6	61
23	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. JAMA - Journal of the American Medical Association, 2019, 322, 746.	7.4	220
24	Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Science Translational Medicine, 2019, 11, .	12.4	99
25	Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma. Leukemia, 2019, 33, 2429-2441.	7.2	24
26	The challenge of defining â€œultraâ€highâ€riskâ€•neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
27	A revised Children's Oncology Group (COG) neuroblastoma risk classification system: Report from the COG biology study ANBL00B1.. Journal of Clinical Oncology, 2019, 37, 10012-10012.	1.6	1
28	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
29	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. The Lancet Child and Adolescent Health, 2018, 2, 25-34.	5.6	38
30	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clinical Cancer Informatics, 2018, 2, 1-15.	2.1	20
31	TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. Cell Reports, 2018, 25, 1255-1267.e5.	6.4	46
32	Characterisation of the p53 pathway in cell lines established from TH-MYCN transgenic mouse tumours. International Journal of Oncology, 2018, 52, 967-977.	3.3	4
33	Myc, Oncogenic Protein Translation, and the Role of Polyamines. Medical Sciences (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5	2.9	28
34	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28
35	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the childrenâ€™s oncology group. Oncotarget, 2018, 9, 6416-6432.	1.8	31
36	NANT 2012-01: Phase 1 study of DFMO and celecoxib with cyclophosphamide and topotecan for relapsed or refractory high-risk neuroblastoma.. Journal of Clinical Oncology, 2018, 36, 10558-10558.	1.6	3

#	Article	IF	Citations
37	Inhibition of the oncogenic fusion protein EWS-FLI1 causes G ₂ -M cell cycle arrest and enhanced vincristine sensitivity in Ewingâ€™s sarcoma. Science Signaling, 2017, 10, .	3.6	51
38	Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer, 2017, 123, 4224-4235.	4.1	97
39	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 675.	4.8	18
40	Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. PLoS ONE, 2016, 11, e0161039.	2.5	21
41	A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma. Oncotarget, 2016, 7, 49246-49258.	1.8	25
42	Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. Clinical Cancer Research, 2016, 22, 4391-4404.	7.0	61
43	Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Childrenâ€™s Oncology Group. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 474-481.	6.4	19
44	Association of age at diagnosis and stage of disease with ATRX mutations in neuroblastoma.. Journal of Clinical Oncology, 2016, 34, 10525-10525.	1.6	2
45	Myeloablative busulfan/melphalan (BuMel) consolidation following induction chemotherapy for patients with high-risk neuroblastoma: A Childrenâ€™s Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, 10528-10528.	1.6	3
46	Impact of KIR/KIR ligand genotype for neuroblastoma patients in a phase III COG immunotherapy trial.. Journal of Clinical Oncology, 2016, 34, e14014-e14014.	1.6	1
47	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	17
48	A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG) study.. Journal of Clinical Oncology, 2016, 34, LBA3-LBA3.	1.6	31
49	Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget, 2016, 7, 21840-21852.	1.8	85
50	TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. Cancer Letters, 2015, 357, 412-418.	7.2	44
51	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
52	EGFR signaling defines Mcl⁻1 survival dependency in neuroblastoma. Cancer Biology and Therapy, 2015, 16, 276-286.	3.4	20
53	Expanding MYCN's Reach in Oncogenic Transcription. Journal of the National Cancer Institute, 2015, 107, djv122-djv122.	6.3	1
54	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. Oncotarget, 2015, 6, 18558-18576.	1.8	26

#	Article	IF	Citations
55	Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. Translational Pediatrics, 2015, 4, 226-38.	1.2	63
56	Abstract A37: Immunohistochemical detection of MYCN protein and MYC protein identifies highly aggressive neuroblastomas. , 2015, , .		0
57	ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma. Cancer Cell, 2014, 26, 682-694.	16.8	302
58	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatric Blood and Cancer, 2013, 60, 985-993.	1.5	285
59	Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nature Genetics, 2013, 45, 12-17.	21.4	374
60	The genetic landscape of high-risk neuroblastoma. Nature Genetics, 2013, 45, 279-284.	21.4	990
61	The Stress Protein BAG3 Stabilizes Mcl-1 Protein and Promotes Survival of Cancer Cells and Resistance to Antagonist ABT-737. Journal of Biological Chemistry, 2013, 288, 6980-6990.	3.4	67
62	Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. Frontiers in Oncology, 2012, 2, 162.	2.8	43
63	Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma. Cancer Research, 2012, 72, 2565-2577.	0.9	65
64	ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation. Cancer Cell, 2012, 22, 631-644.	16.8	309
65	PI3King on MYCN to Improve Neuroblastoma Therapeutics. Cancer Cell, 2012, 21, 145-147.	16.8	16
66	IL-17A in LCH: Systemic Biomarker, Local Factor, or None of the Above?. Molecular Therapy, 2011, 19, 1405-1406.	8.2	10
67	Mcl1 becomes ubiquitin-ous: new opportunities to antagonize a pro-survival protein. Cell Research, 2010, 20, 391-393.	12.0	7
68	Disrupting Polyamine Homeostasis as a Therapeutic Strategy for Neuroblastoma. Clinical Cancer Research, 2009, 15, 5956-5961.	7.0	46
69	Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biology and Therapy, 2009, 8, 1587-1595.	3.4	80
70	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
71	ODC1 Is a Critical Determinant of MYCN Oncogenesis and a Therapeutic Target in Neuroblastoma. Cancer Research, 2008, 68, 9735-9745.	0.9	200
72	Neuroblastoma. Lancet, The, 2007, 369, 2106-2120.	13.7	1,856

#	Article	IF	Citations
73	Mutations in PIK3CAare infrequent in neuroblastoma. BMC Cancer, 2006, 6, 177.	2.6	29
74	Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma. Journal of Clinical Oncology, 2006, 24, 5725-5734.	1.6	84
75	Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene, 2005, 24, 2684-2694.	5.9	147
76	Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma. Cancer Letters, 2005, 228, 133-141.	7.2	79
77	The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Letters, 2003, 197, 173-179.	7.2	58
78	Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features. Clinical Cancer Research, 2003, 9, 3345-55.	7.0	46
79	No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3. Cancer Research, 2002, 62, 6481-4.	0.9	8
80	Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 24-27.	1.0	48
81	Comprehensive analysis of chromosome 1p deletions in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 32-36.	1.0	63
82	Analysis of genomic imprinting at 1p35-36 in neuroblastoma. Medical and Pediatric Oncology, 2001, 36, 52-55.	1.0	16
83	Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 512-515.	1.0	25
84	Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology, 2000, 35, 526-530.	1.0	26
85	Deletion of 11q23 is a frequent event in the evolution ofMYCN single-copy high-risk neuroblastomas. Medical and Pediatric Oncology, 2000, 35, 544-546.	1.0	37
86	BIN1 inhibits colony formation and induces apoptosis in neuroblastoma cell lines withMYCN amplification. Medical and Pediatric Oncology, 2000, 35, 559-562.	1.0	21
87	Loss of Heterozygosity at 1p36 Independently Predicts for Disease Progression But Not Decreased Overall Survival Probability in Neuroblastoma Patients: A Childrenâ€™s Cancer Group Study. Journal of Clinical Oncology, 2000, 18, 1888-1899.	1.6	146
88	Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene, 1999, 18, 4948-4957.	5.9	228